SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc.

Friday, March 3, 2017 4:38 PM UTC

NEW YORK, March 03, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Anthera Pharmaceuticals, Inc. (“Anthera”) (NASDAQ:ANTH) between February 10, 2015 and December 27, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Clevlen v. Anthera Pharmaceuticals, Inc., et al. (Case No. 3:17-cv-715) in the USDC for the Northern District of California. Click here to view the complaint. To get more information go to:

http://www.zlk.com/pslra/anthera-pharmaceuticals-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, among other allegations, throughout the Class Period, Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (i) patients were not improving in the CHABLIS-SC1 clinical trial; and (ii) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Following this news, shares of Anthera fell approximately 32% to close at $1.90 on November 10, 2016. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this news, shares of Anthera fell approximately 63% to close at $0.74 on December 28, 2016.

Take Action: if you suffered a loss in Anthera you have until April 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor 
New York, NY 10004            
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc.

Editor's Picks

Welcome to EconoTimes